Boehringer Ingelheim sales and marketing update

Boehringer launched Stiolto Respimat tiotropium/olodaterol in the U.S. to treat chronic obstructive pulmonary disease (COPD). The wholesale acquisition cost (WAC) for Stiolto Respimat is $315.68 for 60 metered inhalations. Boehringer said it will offer a savings card that will allow “most eligible” patients to get the product at no cost for 12 consecutive months. ...